Current Status of Human Melanoma VaccinesCan They Control Malignant Melanoma?

被引：0
作者：
Dave S. B. Hoon
Reiko F. Irie
机构：
[1] John Wayne Cancer Institute at Saint John’s Hospital and Health Center,Divisions of Molecular & Cellular Immunology and Biotechnology Sciences
来源：
BioDrugs | 1997年 / 7卷
关键词：
Melanoma; Melanoma Cell; Human Leucocyte Antigen; Melanoma Antigen; Melanoma Vaccine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The characterisation of human melanomas as immunogenic and the observation of spontaneous regression have led to the development of active specific immunotherapy in the form of vaccines for treatment of malignant melanoma. These vaccines have recently been the subject of considerable interest, particularly since the introduction of melanoma antigen cloning, the identification of specific peptide sequences recognised by the immune system, and better understanding of antigen presentation. Today, melanoma vaccines are a significant therapeutic agent in treatment of malignant melanoma. There are many melanoma vaccines that are in clinical trials which have produced very encouraging clinical responses. This review discusses the different forms of melanoma vaccines used in the 1990s and their current status in clinical trials.
引用
收藏
页码：66 / 84
页数：18
相关论文
共 313 条
  • [1] Koh HK(1991)Cutaneous melanoma N Engl J Med 325 171-82
  • [2] Barth A(1995)The role of adjuvant therapy in melanoma management Cancer 75 726-34
  • [3] Morton DL(1994)Update on immunotherapy for advanced melanoma Contemp Oncol 4 52-60
  • [4] Barth AM(1992)Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine Ann Surg 216 463-82
  • [5] Irie RF(1991)Common expression of melanoma tumour-associated antigens recognized by human tumour infiltrating lymphocytes: analysis by human lymphocyte antigen restriction J Immunother 10 153-64
  • [6] Morton DL(1993)Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients J Exp Med 177 989-98
  • [7] Morton DL(1989)Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside Cancer Res 49 7045-50
  • [8] Foshag LJ(1981)Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen J Natl Cancer Inst 66 249-54
  • [9] Hoon DS(1992)Immunotherapy for malignant melanoma with a tumour cell vaccine Ann Plast Surg 28 104-7
  • [10] Horn SS(1994)Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside J Clin Oncol 12 1036-44
12345678910